Please login to the form below

Not currently logged in
Email:
Password:

Arresto Biosciences

This page shows the latest Arresto Biosciences news and features for those working in and with pharma, biotech and healthcare.

Gilead chalks up trial success for new NASH drug

Gilead chalks up trial success for new NASH drug

The phase II trial is looking at selonsertib (GS-4997) on its own or in combination with Gilead's other NASH candidate simtuzumab - acquired along with Arresto Biosciences for $225m in

Latest news

  • Priority FDA review for new Gilead HCV combination therapy Priority FDA review for new Gilead HCV combination therapy

    The antibody - which was acquired by Gilead when it bought Arresto Biosciences for $225m in 2010 - has previously failed to show efficacy in a pancreatic cancer trial.

  • Gilead's simtuzumab fails pancreatic cancer trial Gilead's simtuzumab fails pancreatic cancer trial

    Simtuzumab - which was acquired by Gilead when it bought Arresto Biosciences for $225m in 2010 - is also in phase II trials for idiopathic pulmonary fibrosis, myelofibrosis, non-alcoholic steatohepatitis (NASH) and

  • Gilead to acquire Calistoga

    The Calistoga acquisition comes on the heels of the company's acquisitions last year of two other small biotech companies, CGI Pharmaceuticals and Arresto Biosciences, both of which are also developing ... Gilead acquired Arresto for $225m plus potential

  • Gilead to acquire Arresto Bioscences

    Gilead to acquire Arresto Bioscences. Gilead will acquire Arresto Biosciences for $225m plus potential future payments based on sales levels. ... Gilead will acquire Arresto Biosciences for $225m plus potential future payments based on sales levels.

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics